

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

# Natriuretic Peptide Testing for Perioperative Risk Assessment: Clinical Effectiveness, Cost- Effectiveness, and Guidelines

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: July 31, 2019  
Report Length: 7 Pages

**Authors:** Camille Dulong, Suzanne McCormack

**Cite As:** *Natriuretic Peptide Testing for Perioperative Risk Assessment: Clinical Effectiveness, Cost-Effectiveness, and Guidelines*. Ottawa: CADTH; 2019 July. (CADTH rapid response report: summary of abstracts).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Research Questions

1. What is the clinical utility of natriuretic peptide testing for perioperative cardiac risk assessment?
2. What is the cost-effectiveness of natriuretic peptide testing for perioperative cardiac risk assessment?
3. What are the guidelines for natriuretic peptide testing for perioperative cardiac risk assessment?

## Key Findings

One systematic review (with meta-analysis), one non-randomized study and one evidence-based guideline were found regarding natriuretic peptide testing for perioperative cardiac risk assessment.

## Methods

A limited literature search was conducted by an information specialist on key resources including PubMed, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were natriuretic peptide testing and perioperative cardiac risk. For a narrow search, no filters were applied to limit the retrieval by study type. For a broad search, search filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, or network meta-analyses, randomized controlled trials or controlled clinical trials, economic studies and guidelines. The search was also limited to English language documents published between January 1, 2014 and July 17, 2019. Internet links were provided, where available.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Patients of all ages in need of perioperative risk assessment
<b>Intervention</b>	Natriuretic peptide testing (BNP/NT-proBNP blood tests) with/without additional diagnostic test(s)
<b>Comparator</b>	Q1 & 2: No natriuretic peptide testing; Other prognostic testing (cardiac troponin T test, echocardiography); Natriuretic peptide testing in addition to another diagnostic test Q3: Not applicable
<b>Outcomes</b>	Q1: Clinical utility (e.g., changes to therapy) Q2: Cost-effectiveness Q3: Guidelines
<b>Study Designs</b>	Health technology assessments, systematic reviews, randomized-controlled trials, non-randomized studies, economic evaluations and evidence-based guidelines

## Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, economic evaluations, and evidence-based guidelines.

One systematic review (with meta-analysis)<sup>1</sup>, one non-randomized study<sup>2</sup> and one evidence-based guideline<sup>3</sup> were identified regarding natriuretic peptide testing for perioperative cardiac risk assessment. No relevant health technology assessments, systematic reviews, meta-analyses and randomized controlled trials and economic evaluations were identified in the search.

Additional references of potential interest are provided in the appendix.

## Overall Summary of Findings

One systematic review (SR) (with meta-analysis)<sup>1</sup>, one non-randomized study (NRS)<sup>2</sup> and one evidence-based guideline<sup>3</sup> were identified regarding natriuretic peptide (NP) testing for perioperative cardiac risk assessment.

The identified SR<sup>1</sup> evaluated whether perioperative NP testing would predict post-operative major adverse cardiac events. The SR included 24 eligible articles and concluded that perioperative NP testing had reasonable accuracy and could be useful in perioperative risk stratification and predicting post-operative major adverse cardiac events.<sup>1</sup>

Secondly, the NRS<sup>2</sup> examined whether plasma brain NP levels and early morbidity were associated with patients undergoing coronary artery bypass. Twenty-two patients undergoing coronary artery bypass surgery were included in the study with pre-operative plasma brain NP levels compared to postoperative morbidity findings. Overall, the researchers concluded that preoperative plasma brain NP levels were a reliable indicator for early postoperative morbidity in patients undergoing coronary artery bypass.

Finally, the identified guideline<sup>3</sup> by the American College of Cardiology/American Heart Association Task Force states that biomarkers may be a helpful tool to predict post-operative morbidity although data is limited as to whether targeting these biomarkers for treatment will reduce post-operative risk.

## References Summarized

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

1. Young YR, Sheu BF, Li WC, et al. Predictive value of plasma brain natriuretic peptide for postoperative cardiac complications--a systemic review and meta-analysis. *J Crit Care*. 2014 Aug;29(4):696.e691-610.  
[PubMed: PM24793659](https://pubmed.ncbi.nlm.nih.gov/24793659/)

## Randomized Controlled Trials

No literature identified.

## Non-Randomized Studies

2. Avsar MK, Yaliniz H. Preoperative Serum NT-proBNP levels; Can it be a Clue About Postoperative Clinical Outcome of Patients Undergoing to Coronary Artery Bypass Surgery? *J Cardiol & Cardiovasc Ther* 2016; 1(5)1-6.  
<https://pdfs.semanticscholar.org/e4f3/cb7e1106876de3ef7ad8d5b0a6eb40c0a9f0.pdf>

## Economic Evaluations

No literature identified.

## Guidelines and Recommendations

3. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Dec 9;130(24):e278-333. <https://www.ahajournals.org/doi/10.1161/CIR.000000000000106>

*See: Section 2: Clinical Risk Factors*

## Appendix — Further Information

### Health Technology Assessments

#### *Perioperative Setting Not Specified*

4. Pufulete M, Maishman R, Dabner L, et al. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. *Health Technol Assess* 2017;21(40); <https://www.journalslibrary.nihr.ac.uk/hta/hta21400/#/abstract>

### Non-Randomized Studies

#### *Perioperative Setting Not Specified*

5. Youssef H, Collantes E, Hunter J, et al. Preoperative and Postoperative N-terminal Pro B-type Natriuretic Peptide Levels Predict Cardiac Morbidity and Mortality in Patients Undergoing Colorectal Cancer Resection. *J Colon Rectal Cancer*. 2019;1(3):1-9. <https://openaccesspub.org/jcrc/article/948>

### Evidence-Based Guidelines

#### *Perioperative Setting Not Specified*

6. National Institute in Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. (*NICE guideline NG106*); 2018; <https://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685> Accessed 2019 Jul 29
7. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Can J Cardiol*. 2017 Nov;33(11):1342-1433. [https://www.onlinecjc.ca/article/S0828-282X\(17\)30973-X/pdf](https://www.onlinecjc.ca/article/S0828-282X(17)30973-X/pdf)
8. Scottish Intercollegiate Guidelines Network. Management of chronic heart failure: a national clinical guideline. (*SIGN 147*); 2016; <https://www.sign.ac.uk/assets/sign147.pdf> Accessed 2019 Jul 29
9. Moe GW, Ezekowitz JA, O'Meara E, et al. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. *Can J Cardiol*. 2015 Jan;31:3-16. [https://www.onlinecjc.ca/article/S0828-282X\(14\)01492-5/pdf](https://www.onlinecjc.ca/article/S0828-282X(14)01492-5/pdf)
10. National Institute in Health and Care Excellence. Acute heart failure: diagnosis and management. (*NICE Clinical guideline CG187*). 2014; <https://www.nice.org.uk/guidance/cg187/resources/acute-heart-failure-diagnosis-and-management-pdf-35109817738693> Accessed 2019 Jul 29
11. Klings ES, Machado RF, Barst RJ, et al. An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. *Am J Respir Crit Care Med*. 2014 Mar 15;189(6):727-40; <http://www.thoracic.org/statements/resources/pvd/sickle-cell-disease.pdf>

## Clinical Practice Guidelines – Methodology Not Specified

12. Guidelines & Protocols Advisory Committee. Chronic heart failure – diagnosis and management. Victoria (BC): BCGuidelines.ca; 2015; <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/heart-failure-chronic> Accessed 2019 Jul 29

## Review Articles

13. Soussi S, Chatti K, Mebazaa A. Management of perioperative heart failure. *Curr Opin Anesthesiol.* 2014, 27:140–145. [https://sfai.se/wp-content/uploads/2018/05/Management\\_of\\_perioperative\\_heart\\_failure.5.pdf](https://sfai.se/wp-content/uploads/2018/05/Management_of_perioperative_heart_failure.5.pdf)

## Additional References

14. Cantinotti M, Walters HL, Crocetti M, Marotta M, Murzi B, Clerico A. BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use? *Cardiol Young.* 2015 Mar;25(3):424-437. [PubMed: PM25601330](#)
15. Ma J, Xin Q, Wang X, Gao M, Wang Y, Liu J. Prediction of Perioperative Cardiac Events through Preoperative NT-pro-BNP and cTnI after Emergent Non-Cardiac Surgery in Elderly Patients. *PLoS ONE.* 2015;10(3): e0121306 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0121306>
16. Shang C. B-type natriuretic peptide-guided therapy for perioperative medicine? *Open heart.* 2014;1(1):e000105. [PubMed: PM25332815](#)
17. Wayne Causey M, Singh N. Clinical implications of B-type natriuretic peptide and N-terminal pro--B-type natriuretic peptide in the care of the vascular surgery patient. *Semin Vasc Surg.* 2014 Dec;27(3-4):143-147. [PubMed: PM26073822](#)